NYPI JOURNAL CLUB
STEREOTACTIC HYPOFRACTIONATED ACCURATE RADIOTHERAPY OF
- Berit L. Madsen, M.D.,* R. Alex Hsi, M.D.,* Huong T. Pham, M.D.,* Jack F. Fowler, D.Sc., Ph.D., Laura Esagui, C.M.D.,* And John Corman, M.D.! *Sections of Radiation Oncology and !Urology, Virginia Mason Medical Center, Seattle, WA; Emeritus, Department of Human Oncology, Medical School, University of Wisconsin, Madison, WI
Read More ›
A comparison of overall survival between patients with low- and intermediate-risk prostate cancer treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
- J. P. Ciezki, C. A. Reddy, P. A. Kupelian, E. A. Klein, C. Robinson, N. Chehade, K. Angermeier, A. Altman, J. Ulchaker
Read More ›
Prostate Cancer in Fathers With Fewer Male Offspring: the Jerusalem Perinatal Study Cohort
- Susan Harlap, Ora Paltiel, Yehiel Friedlander, Ronit Calderon-Margalit, Lisa Deutsch, Karinne R. Kleinhaus, Orly Manor, Alfred I. Neugut, Mark Opler, Mary C. Perrin, Mary B. Terry, Efrat Tiram, Rivka Yanetz
Affliliations of authors: Department of Epidemiology, Mailman School of Public Health (SH, AIN, MO, MCP, MBT), and Department of Psychiatry (KRK), Columbia University, New York, NY; Epidemiology Unit, Braun School of Public Health, Hebrew University-Hadassah School of Public Health, Jerusalem, Israel (OP, YF, RCM, LD, OM, ET, RY)
Read More ›
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
- Greenspan SL, Nelson JB, Trump DL, Resnick NM.University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Read More ›
Prostate Specific Antigen Density Correlates
- Shilajit D. Kundu, Kim Yu, Jo Ann V. Antenor, Brian K. Suarez and William J. Catalona, Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (SDK, XY, WJC), and the Departments of Psychiatry (KAR, BKS) and Neurology (JVA), Washington University, School of Medicine, St. Louis, Missouri
Read More ›
Next 5
|
|
|
April 24, 2007 - Introduction:
Evaluation of the factors thought to influence overall survival (OS) in patients treated for low and intermediate-risk prostate cancer (CaP) with brachytherapy (PI), external beam radiotherapy (RT), or prostatectomy (RP).
Methods:
From 1996 to 2003, 2,285 patients with low or intermediate-risk CaP were treated at the Cleveland Clinic with either PI (n=662), RT (n=570), or RP (n=1,053). Factors thought to influence OS were recorded. The following factors were included in this analysis: Charlson score (a validated co-morbidity index), age, socioeconomic status using median household income by zip code, race, body mass index, presence of coronary artery disease, presence of hypertension, presence of dyslipidemia, initial prostate-specific antigen, biopsy Gleason score, clinical stage, use of androgen deprivation (AD), AD duration, smoking history including pack-years, alcohol use, and cancer treatment modality. Univariate and multivariate analyses were done using Cox proportional hazards regression.
Results:
The median follow-up is 59 months (range: 24-119 mo.). Patients treated with PI had the greatest co-morbidity burden (mean Charlson scores for PI: 0.62, RT: 0.34, and RP: 0.20; overall range: 0-7). The median dose of radiation for the RT patients was 82.9 Gy (range: 68.4-82.9 Gy). All PI patients received 144 Gy. The 5-year OS rate is 96.0%; the 8-year rate is 89.9%. RT patients had the lowest OS rates of the three modalities. The results of the univariate and multivariate analyses of factors significantly affecting OS are shown in the Table. Treatment with RT was independently associated with worse OS relative to PI and RP. AD, socioeconomic status, and race were not found to affect OS.
Conclusions:
Charlson score, age, smoking history, and treatment modality independently affect OS in patients treated for low and intermediate-risk prostate cancer.
|
